VIVS Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017βFY2026
VivoSim Labs, INC. had $0.1M of revenue in fiscal 2026, down 9.0% on the year before.
Last close Β· Oct 23, 2026
$0.15
6.8%Hi! I read VivoSim Labs, INC.βs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
β9.0%
No. Sales fell 9.0% last year.
Does it make a profit?
β10,567.2%
No. It lost money last year.
Does profit turn into cash?
β8,264.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days VivoSim Labs, INC. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q1 '27 | Before the market opens | 8-K β |
| Jul 14, 2026 | Q4 '26 | After the market closes | 10-K β |
| Feb 11, 2026 | Q3 '26 | After the market closes | 10-Q β |
| Nov 6, 2025 | Q2 '26 | After the market closes | 10-Q β |
| Aug 12, 2025 | Q1 '26 | After the market closes | 10-Q β |
| Apr 2, 2025 | Q4 '25 | Before the market opens | 8-K β |
| Feb 19, 2025 | Q3 '25 | Before the market opens | 10-Q β |
| Nov 8, 2024 | Q2 '25 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· VivoSim Labs, INC. had $0.1M of revenue in fiscal 2026, down 9.0% on the year before. Its operating margin was β8,768.7%, down 7.6Β pts: of every 100 in sales, about β8,769 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· VivoSim Labs, INC. lost $13.8M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$10.8M in fiscal 2026, β8,264.9% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably VivoSim Labs, INC. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $28.7M | $15.3M | $2.9M | $11.3M | $5.0M |
| Interest coverage | β | β | β | β1,261.6x | β957.3x |
| Current ratio | 21.4x | 4.6x | 2.1x | 3.2x | 2.4x |
| Quick ratio | 21.4x | 4.6x | 2.0x | 3.2x | 2.4x |
| Total assets | $33.3M | $20.3M | $6.3M | $14.7M | $7.4M |
| Total liabilities | $3.1M | $5.0M | $2.7M | $4.2M | $8.5M |
| Shareholders' equity | $30.2M | $15.3M | $3.6M | $10.5M | β$1.1M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· VivoSim Labs, INC. passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 4 / 8 | 5 / 8 | 3 / 7 | 3 / 7 | 1 / 7 | 2 / 7 | 2 / 7 | 3 / 8 |
| Accruals ratio | β13.4% | β10.0% | β13.8% | β11.1% | β10.2% | β8.2% | β18.1% | β0.1% | 66.4% | β27.4% |
| Altman Z'' | 2.07 | β5.60 | β11.00 | β15.54 | 36.24 | β16.63 | β50.47 | β186.86 | β75.52 | β164.30 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.2M | $4.6M | $3.1M | $2.2M | $0.0M | $1.5M | $0.4M | $0.1M | $0.1M | $0.1M |
| Gross profit | $3.3M | $3.6M | $2.6M | $1.9M | $0.0M | β | β | β | $0.1M | $0.1M |
| Research and development | $19.5M | $18.0M | $14.8M | $5.3M | $1.1M | $3.3M | $8.9M | $5.5M | $5.0M | $4.2M |
| Operating income | β$38.6M | β$35.3M | β$27.3M | β$21.5M | β$16.8M | β$11.5M | β$17.7M | β$15.1M | β$12.6M | β$11.5M |
| Interest expense | $0.0M | β | β | β | β | β | β | β | $0.0M | $0.0M |
| Pretax income | β | β | β | β | β | β | β | β | β$2.5M | β$13.8M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$38.4M | β$34.8M | β$26.6M | β$18.7M | β$16.8M | β$11.4M | β$17.3M | β$14.7M | β$2.5M | β$13.8M |
| Diluted EPS | β$0.39 | β$0.32 | β$0.23 | β$2.80 | β$2.44 | β$1.32 | β$1.98 | β$19.25 | β$1.70 | β$5.35 |
| Diluted shares | 0.10B | 0.11B | 0.12B | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$29.2M | β$28.9M | β$20.4M | β$14.9M | β$13.3M | β$8.5M | β$12.4M | β$14.7M | β$9.5M | β$10.8M |
| Capital expenditure | $1.4M | $0.2M | $0.1M | $0.0M | $0.4M | $0.4M | $0.4M | $0.0M | $0.0M | $0.0M |
| Free cash flow | β$30.5M | β$29.1M | β$20.5M | β$14.9M | β$13.7M | β$8.9M | β$12.8M | β$14.7M | β$9.5M | β$10.8M |
| Depreciation and amortization | $1.1M | $1.3M | $1.0M | $1.1M | $0.0M | $0.1M | $0.3M | $0.3M | $0.3M | $0.2M |
| Stock-based compensation | $7.4M | $6.9M | $5.2M | $4.1M | $5.6M | $2.3M | $2.4M | $1.5M | $0.5M | $0.3M |
| Share buybacks | β | β | β | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Dividends and buybacks | β | β | β | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $62.8M | $43.7M | $36.5M | $27.4M | $37.4M | $28.7M | $15.3M | $2.9M | $11.3M | $5.0M |
| Current assets | $65.1M | $46.8M | $38.6M | $28.3M | $38.4M | $29.5M | $17.0M | $3.9M | $12.1M | $6.6M |
| Current liabilities | $6.0M | $4.7M | $3.7M | $1.8M | $0.7M | $1.4M | $3.7M | $1.9M | $3.7M | $2.8M |
| Inventory | $0.6M | $0.8M | $0.5M | $0.0M | β | β | $0.0M | $0.3M | $0.0M | β |
| Property and equipment, net | $3.8M | $2.8M | $1.8M | $0.0M | $0.4M | $0.7M | $0.9M | $0.7M | $0.4M | $0.2M |
| Total assets | $69.2M | $49.8M | $40.6M | $28.4M | $39.9M | $33.3M | $20.3M | $6.3M | $14.7M | $7.4M |
| Total liabilities | $6.8M | $5.2M | $4.3M | $1.8M | $0.7M | $3.1M | $5.0M | $2.7M | $4.2M | $8.5M |
| Shareholders' equity | $62.4M | $44.6M | $36.3M | $26.6M | $39.2M | $30.2M | $15.3M | $3.6M | $10.5M | β$1.1M |
| Margins | ||||||||||
| Gross margin | 77.4% | 78.3% | 83.8% | 86.3% | β | β | β | β | 96.5% | 100.0% |
| Operating margin | β911.9% | β766.3% | β882.4% | β977.9% | β | β765.3% | β4,792.2% | β13,840.4% | β8,761.1% | β8,768.7% |
| EBITDA margin | β884.8% | β738.7% | β850.7% | β925.9% | β | β755.8% | β4,713.0% | β13,583.5% | β8,576.4% | β8,604.6% |
| Net margin | β908.9% | β756.1% | β861.7% | β852.0% | β | β763.2% | β4,664.6% | β13,459.6% | β1,727.8% | β10,567.2% |
| FCF margin | β722.0% | β631.8% | β661.7% | β677.7% | β | β590.8% | β3,460.5% | β13,481.7% | β6,579.2% | β8,264.9% |
| Returns | ||||||||||
| Return on capital employed | β61.1% | β78.1% | β73.9% | β80.6% | β42.9% | β36.0% | β106.5% | β336.1% | β115.6% | β249.7% |
| Return on equity | β61.7% | β65.1% | β65.9% | β59.5% | β51.1% | β33.0% | β75.8% | β155.0% | β35.3% | β294.8% |
| Return on assets | β55.6% | β58.5% | β58.9% | β54.2% | β49.2% | β31.3% | β64.4% | β110.1% | β23.7% | β125.6% |
| Return on tangible equity | β61.7% | β78.1% | β73.4% | β70.3% | β42.9% | β37.9% | β112.6% | β407.4% | β23.7% | β |
| Growth | ||||||||||
| Revenue growth | β | 8.8% | β32.8% | β29.0% | β100.0% | β | β75.3% | β70.5% | 32.1% | β9.0% |
| Share count change | β | 9.7% | 7.6% | β94.4% | 6.5% | 26.1% | 0.1% | β91.3% | 92.0% | 76.8% |
| Financial health | ||||||||||
| Interest coverage | β | β | β | β | β | β | β | β | β1,261.6x | β957.3x |
| Current ratio | 10.8x | 10.0x | 10.3x | 15.6x | 53.3x | 21.4x | 4.6x | 2.1x | 3.2x | 2.4x |
| Quick ratio | 10.7x | 9.9x | 10.2x | 15.6x | 53.3x | 21.4x | 4.6x | 2.0x | 3.2x | 2.4x |
| Capital allocation | ||||||||||
| Capex / revenue | 32.0% | 4.9% | 2.6% | 0.0% | β | 27.3% | 107.0% | 38.5% | 9.0% | 0.0% |
| Stock comp / revenue | 174.8% | 150.0% | 168.0% | 187.1% | β | 150.4% | 642.4% | 1,383.5% | 369.4% | 231.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 4.0 | 5.0 | 3.0 | 3.0 | 1.0 | 2.0 | 2.0 | 3.0 |
| Altman Z'' | 2.1 | β5.6 | β11.0 | β15.5 | 36.2 | β16.6 | β50.5 | β186.9 | β75.5 | β164.3 |
| Accruals ratio | β13.4% | β10.0% | β13.8% | β11.1% | β10.2% | β8.2% | β18.1% | β0.1% | 66.4% | β27.4% |
Source: SEC EDGAR XBRL filings (CIK 0001497253). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
